885 AVOIDING ANDROGEN DEPRIVATION THERAPY IN MEN WITH HIGH RISK PROSTATE CANCER: THE ROLE OF RADICAL PROSTATECTOMY AS INITIAL TREATMENT

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced1 Apr 2011885 AVOIDING ANDROGEN DEPRIVATION THERAPY IN MEN WITH HIGH RISK PROSTATE CANCER: THE ROLE OF RADICAL PROSTATECTOMY AS INITIAL TREATMENT Ranko Miocinovic, Ryan K. Berglund, Andrew J. Stephenson, J. Stephen Jones, Amr F. Fergany, Jihad Kaouk, and Eric A. Klein Ranko MiocinovicRanko Miocinovic Cleveland, OH More articles by this author , Ryan K. BerglundRyan K. Berglund Cleveland, OH More articles by this author , Andrew J. StephensonAndrew J. Stephenson Cleveland, OH More articles by this author , J. Stephen JonesJ. Stephen Jones Cleveland, OH More articles by this author , Amr F. FerganyAmr F. Fergany Cleveland, OH More articles by this author , Jihad KaoukJihad Kaouk Cleveland, OH More articles by this author , and Eric A. KleinEric A. Klein Cleveland, OH More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.751AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To examine the ability of surgery as initial management in avoiding androgen deprivation therapy (ADT) in patients with high risk localized prostate cancer. METHODS A total of 267 men were identified from a cohort of patients treated by radical prostatectomy (RP) between January 1998 and June 2004. Patients were included if they presented with clinical stage >T2b, and/or prostate specific antigen (PSA) Ý15 ng/ml, and/or Gleason score ÝY 8. Information on biochemical recurrence, distant metastasis, cancer specific survival, and use of ADT was obtained from a prospectively maintained database. RESULTS The mean follow-up was 6.7 years (range, 1–146 months). Biochemical recurrence (BCR), distant metastasis (DM), and death from prostate cancer were observed in 112 (42%), 28 (10%), and 15 (6%) patients, respectively. Salvage treatment was performed in 95 (85%) of 112 patients with BCR. Only 71 (27%) of 267 men were subjected to ADT. Overall, 10 year probabilities of freedom from BCR, DM, death from prostate cancer, and ADT were 59% (95% CI, 53–65), 89% (95% CI, 85–92), 94% (95% CI, 91–97), and 73% (95% CI, 68–79), respectively. CONCLUSIONS RP provides excellent long-term clinical outcomes for patients with high risk localized prostate cancer and avoids the use of ADT in approximately 70% of these patients. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e354 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ranko Miocinovic Cleveland, OH More articles by this author Ryan K. Berglund Cleveland, OH More articles by this author Andrew J. Stephenson Cleveland, OH More articles by this author J. Stephen Jones Cleveland, OH More articles by this author Amr F. Fergany Cleveland, OH More articles by this author Jihad Kaouk Cleveland, OH More articles by this author Eric A. Klein Cleveland, OH More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...